DC
RVMD icon

Diametric Capital’s Revolution Medicines RVMD Stock Holding History

Diametric Capital’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.46M Buy
+15,000
New +$1.51M 0.38% 59

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Diametric Capital's RVMD Position: Q1 2026 in Review

Diametric Capital opened a new position in Revolution Medicines (RVMD) in Q1 2026: 15,000 shares worth $1.46M. The stake represents 0.38% of the portfolio and ranks #58 among its holdings. This is a return to the name: Diametric Capital previously reported a position in RVMD as recently as Q2 2025.

Diametric Capital first reported a position in RVMD in Q2 2025 and has held it in 2 quarters since. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • Diametric Capital held 15,000 shares of Revolution Medicines worth $1.46M as of Q1 2026.
  • Revolution Medicines was a new Diametric Capital position in Q1 2026.
  • Revolution Medicines made up 0.38% of Diametric Capital's portfolio in Q1 2026, its #58 holding.
  • Diametric Capital first reported a position in Revolution Medicines in Q2 2025 and has held it in 2 quarters since.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Diametric Capital's 13F filing for Q1 2026, filed 15 May 2026.